Table 4.
Association of treatment, change in laboratory markers, and disease activity during follow-up with subsequent uveitis reactivation
| Parameter | OR; 95% CI | P value |
|---|---|---|
| Laboratory marker | ||
| ESR | 1.02; 0.92, 1.13 | 0.738 |
| CRP | 0.89; 0.67, 1.19 | 0.433 |
| S100A12 | 1.01; 0.98, 1.00 | 0.203 |
| Disease activity | ||
| cJADAS-10 >4.5 | 1.84; 1.18, 7.02 | 0.017 |
| Physician’s global, NRS | 0.80; 0.33, 1.96 | 0.626 |
| CHAQ | 0.04; 0.01, 33.51 | 0.341 |
| Parent’s global | 1.05; 0.57, 1.93 | 0.878 |
| Pain, NRS | 1.15; 0.70, 1.89 | 0.58 |
| Uveitis activity, AC cell grade/involved eye | 2.04; 1.27, 3.26 | 0.003 |
| Tyndall/involved eye | 5.65; 2.09, 15.26 | 0.001 |
| Visual acuity/involved eye, logMAR | 0.60; 0.07, 4.99 | 0.632 |
| Any uveitis eye complications | 1.05; 0.65, 1.48 | 0.198 |
| Anti-inflammatory treatment | ||
| NSAID | 1.41; 0.40, 4.95 | 0.591 |
| Any DMARD | — | |
| MTX | — | |
| Etanercept ± MTX | — | |
| Adalimumab ± MTX | 1.03; 0.26, 4.05 | 0.966 |
| CS, systemic | 1.62; 0.27, 9.77 | 0.596 |
| CS, topical in involved eyes | 3.47; 1.36, 8.86 | 0.01 |
Subsequent uveitis reactivation (n = 16; 30.2%) until 2 years of follow-up, after achieving uveitis inactivity ≥6 months. P-value of less than 0.05 are indicated in bold. AC: anterior cell; CHAQ: Childhood Health Assessment Questionnaire; cJADAS: clinical juvenile arthritis disease activity score; CS: corticosteroids; NRS: numeric rating scale; OR: odds ratio; PedsQL: Pediatric Quality of Life Inventory.